Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41415-022-4602-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The recent landscape of RSV vaccine research.
Ther Adv Vaccines Immunother
January 2025
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX1 2JD, UK.
Respiratory syncytial virus (RSV) causes a significant burden of acute respiratory illness across all ages, particularly for infants and older adults. Infants, especially those born prematurely or with underlying health conditions, face a high risk of severe RSV-related lower respiratory tract infections (LRTIs). Globally, RSV contributes to millions of LRTI cases annually, with a disproportionate burden in low- and middle-income countries (LMICs).
View Article and Find Full Text PDFMenopausal Hormone Therapy for Women With Schizophrenia: What's Stopping Us?
Am J Psychiatry
October 2024
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, U.K. (Reilly and McCutcheon); Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, U.K. (Reilly and McCutcheon); Oxford Health NHS Foundation Trust, Oxford, U.K. (McCutcheon).
What's the rush!: A look at "modified rush" protocols and optimal stopping doses.
Ann Allergy Asthma Immunol
November 2023
Dilley Allergy and Asthma Specialists, San Antonio, Texas. Electronic address:
Despite the documented success of gonadotropin-releasing hormone analogs (GnRHa) for the treatment of treatment-resistant premenstrual dysphoric disorder (PMDD), many patients struggle to find providers who have sufficient knowledge of PMDD and its evidence-based treatments and/or who are comfortable treating PMDD after first-line treatment options have failed. Here, we discuss the barriers to initiating GnRHa for treatment-resistant premenstrual dysphoric disorder (PMDD) and offer practical solutions to address these barriers for providers who encounter patients with treatment-resistant PMDD but may not have the necessary expertise or comfort with providing evidence-based treatments (ie, gynecologists, general psychiatrists). We have included supplementary materials including patient and provider handouts, screening tools, and treatment algorithms with the hope that this review may serve as a primer on PMDD and the use of GnRHa with hormonal addback as a treatment, as well as a guideline for clinicians delivering this treatment to patients in need.
View Article and Find Full Text PDFWhat's stopping the waste-treatment industry from adopting emerging circular technologies? An agent-based model revealing drivers and barriers.
Resour Conserv Recycl
March 2023
Flanders Research Institute for Agriculture, Fisheries and Food, Burg. van Gansberghelaan 115 b2, Merelbeke, 9820, Belgium.
Many new circular economy technologies are gaining momentum, yet research on the complexity of adoption decisions driven by uncertainties, both at technology and ecosystem level, is lacking. In the present study, an agent-based model was developed to study factors that influence the adoption of emerging circular technologies. The case of the waste treatment industry was chosen, specifically its (non-) adoption of the so-called "Volatile Fatty Acid Platform", a circular economy technology that facilitates both the valorization of organic waste into high-end products as well as their sale on global markets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!